Lilly to buy three vaccine developers for nearly $4 billion in infectious disease push - Reuters

5 sources covered this ⚠ Left-only compare →

All three outlets report on the acquisition, but they differ in emphasis. The Globe and Mail highlights Lilly's strategic shift into new therapeutic areas, while STAT News focuses on the potential impact of the acquisition on the vaccine…